| UHC Commercial Medical & Drug | Minimally Invasive Spine Surgery Procedures – Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Tepezza® (Teprotumumab-Trbw) – Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Tezspire® (Tezepelumab-Ekko) – Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Total Artificial Disc Replacement for the Spine – Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Transcranial Magnetic Stimulation for Treating Physical Health Conditions – Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| Meridian Illinois Medicaid Clinical | Brand Name Override | 2026-02-01 |
| Meridian Illinois Medicaid Clinical | Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists | 2026-02-01 |
| Meridian Illinois Medicaid Clinical | Abaloparatide (Tymlos) | 2026-02-01 |
| Meridian Illinois Medicaid Clinical | Abiraterone (Zytiga, Yonsa) | 2026-02-01 |
| Meridian Illinois Medicaid Clinical | Acalabrutinib (Calquence) | 2026-02-01 |